Amengual, J. E., Lichtenstein, R., Lue, J., Sawas, A., Deng, C., Lichtenstein, E., . . . O’Connor, O. A. (2018). A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood.
استشهاد بنمط شيكاغوAmengual, Jennifer E., et al. "A Phase 1 Study of Romidepsin and Pralatrexate Reveals Marked Activity in Relapsed and Refractory T-cell Lymphoma." Blood 2018.
MLA استشهادAmengual, Jennifer E., et al. "A Phase 1 Study of Romidepsin and Pralatrexate Reveals Marked Activity in Relapsed and Refractory T-cell Lymphoma." Blood 2018.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.